sanjivani parenteral

4
BSE Code : 531569 NSE Code : Sector : PHARMACEUTICALS Report date : Thu Apr 24 06:54:00 EDT 2014 Industry overview Market Cap Market Cap is the price of all the outstanding common shares if we were to buy it all at the current price 9.14 Cr The benchmark company Sun Pharma in the pharmaceuticals sector is 14225 times the size of Sanjivani Parenteral Ultra Small Caps are a choice for people who can handle very high volatility/risk with very low liquidity 1

Upload: good-investory

Post on 06-May-2015

41 views

Category:

Business


0 download

TRANSCRIPT

Page 1: Sanjivani parenteral

BSE Code : 531569

NSE Code :

Sector : PHARMACEUTICALSReport date : Thu Apr 24 06:54:00 EDT 2014

Industry overview

Market CapMarket Cap is the price ofall the outstandingcommon shares if we wereto buy it all at the currentprice

9.14 Cr

The benchmark companySun Pharma in thepharmaceuticals sector is14225 times the size ofSanjivani Parenteral

Ultra Small Caps are achoice for people who canhandle very highvolatility/risk with very lowliquidity

1

Page 2: Sanjivani parenteral

Stock AnalysisGrowth Analysis

Companies that have grown historically are more likely to exibit similar growth in the future. Read

the trends in the 4 year annualized profit growth, book value growth and sales growth shown

below:

How good are the returns?

RoE is the speed at which the company might grow without sorting to additional fund raising.

RoCE is the growth speed, if the company used all the assets, including loans/preference shares.

The 2-year and 4-year values give a reasonable assurance about the growth sustenance.

KEY

KEY

2

Page 3: Sanjivani parenteral

Piotroski ScoreSeperate Winners from Losers

The Piotroski scoring system is a nine point system to determine the strength of a firm's financial

position. The score was developed by an accounting professor out of Chicago named Joseph

Piotroski. If it scores an 8 or 9, then the fundamentals are great for the stock.

Score: 6/9

3

Page 4: Sanjivani parenteral

DISCLAIMER

This report is prepared by the good.inve.story. software and is not prepared by an

actual person who has a CFA or any other certification.

good.inve.story. is still in BETA mode. So, please let us know if you find any errors.

We would love to hear from you.

This report is based on information obtained from public sources and sources

believed to be reliable, but no independent verification has been made nor is its

accuracy or completeness guaranteed.

This report is not an advisory to buy or sell. Please buy only if you think, this is the

right company at the right price and sell only if you don’t see any potential for

upside.

get more @ goodinvestory.com

4